Escitalopram Treatment of Night Eating Syndrome

Duke University

Status: Completed

Conditions: Night Eating Syndrome

Treatments: Drug: Placebo; Drug: Escitalopram

Study type: Interventional

Funder types: Other

Identifiers

NCT00636649

LXP-MD-128A

Pro00007133

Details and patient eligibility

About

Night-Eating Syndrome (NES) is an eating disorder characterised by excessive eating at night, sleep disturbance and morning anorexia. This 12-week study examines the effect of escitalopram on symptoms of NES.

Enrollment: 40 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-70 years
• Presence of NES
• BMI 25-50

Exclusion criteria

• History of schizophrenia or other psychoses
• History of bipolar disorder, anorexia nervosa, bulimia, binge eating disorder
• Current major depressive disorder
• Suicidal ideation
• Psychotropic drugs in the past month
• Drugs or herbal remedies that significantly affect body weight, current participation in a weight loss program, currently following a specialized diet (e.g., Atkins, Zone, etc)
• Lack of benefit with SSRI treatment for NES
• Serious or unstable medical illness
• Allergy or hypersensitivity to escitalopram
• Pregnant, breast-feeding, or planning pregnancy in the next six months.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

A

Experimental group

Description:

Escitalopram

Treatment:

Drug: Escitalopram

B

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo